- Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven 1
- 2 immune activation in Sjögren's Disease.
- Sarthak Gupta^{1†}, Eiko Yamada^{2†}, Hiroyuki Nakamura³, Paola Perez², Thomas J.F. Pranzatelli³, 3
- Kalie Dominick², Shyh-Ing Jang², Mehdi Abed², Daniel Martin⁴, Peter Burbelo⁴, Changyu Zheng⁴, 4
- Ben French³, Ilias Alevizos², Zohreh Khavandgar^{2,5}, Margaret Beach⁵, Eileen Pelayo⁵, Brian 5
- Walitt⁵, Sarfaraz Hasni¹, Mariana J. Kaplan^{1,6}, Mayank Tandon², M. Teresa Magone⁷, David E. 6
- Kleiner⁸, John A. Chiorini³, Alan N. Baer⁵, Blake M. Warner^{2,5†^} 7
- 8 [†]These authors contributed equally to this work.
- 9 ^ - lead and supervised this work

- 1. Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin 11
- 12 Diseases, National Institutes of Health, Bethesda MD, USA.
- 2. Salivary Disorder Unit, National Institute of Dental and Craniofacial Research, National 13
- 14 Institutes of Health, Bethesda, MD, USA.
- 3. Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial 15
- 16 Research, National Institutes of Health, Bethesda, MD, USA.
- 17 4. Genomics and Computational Biology Core, National Institute of Dental and Craniofacial
- Research, National Institutes of Health, Bethesda, MD, USA. 18
- 19 5. NIDCR Sjögren's Disease Clinic, National Institute of Dental and Craniofacial Research,
- 20 National Institutes of Health, Bethesda, MD, USA.
- 21 6. Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin
- 22 Diseases, National Institutes of Health, Bethesda MD, USA.

23 7. Consult Services Section, National Eye Institute, National Institutes of Health, Bethesda MD, 24 USA. 25 8. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National 26 Institutes of Health, Bethesda MD, USA. 27 Please address correspondence to: 28 29 (A) Sarthak Gupta (sarthak.gupta@nih.gov) 30 (B) Eiko Yamada (eiko.yamada@nih.gov) 31 (C) Blake M. Warner (blake.warner@nih.gov) 32 **Word Count:** 3994 (< 4000 words) 33 34 **Number of Tables:** 0 **Number of Figures:** 7 35 36 References: 48

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Abstract Objectives: Inflammatory cytokines that signal through the JAK- STAT pathway, especially interferons (IFNs), are implicated in Sjögren's Disease (SjD). Although inhibition of JAKs is effective in other autoimmune diseases, a systematic investigation of IFN-JAK-STAT signaling and effect of JAK inhibitor (JAKi) therapy in SjD-affected human tissues has not been reported. Methods: Human minor salivary glands (MSGs) and peripheral blood mononuclear cells (PBMCs) were investigated using bulk or single cell (sc) RNA sequencing (RNAseq), immunofluorescence microscopy (IF), and flow cytometry. Ex vivo culture assays on PBMCs and primary salivary gland epithelial cell (pSGEC) lines were performed to model changes in target tissues before and after JAKi. **Results:** RNAseq and IF showed activated JAK-STAT pathway in SjD MSGs. Elevated IFNstimulated gene (ISGs) expression associated with clinical variables (e.g., focus scores, anti-SSA positivity). scRNAseq of MSGs exhibited cell-type specific upregulation of JAK-STAT and ISGs; PBMCs showed similar trends, including markedly upregulated ISGs in monocytes. Ex vivo studies showed elevated basal pSTAT levels in SjD MSGs and PBMCs that were corrected with JAKi. SjD-derived pSGECs exhibited higher basal ISG expressions and exaggerated responses to IFNβ, which were normalized by JAKi without cytotoxicity. Conclusions: SjD patients' tissues exhibit increased expression of ISGs and activation of the JAK-STAT pathway in a cell type-dependent manner. JAKi normalizes this aberrant signaling at the tissue level and in PBMCs, suggesting a putative viable therapy for SjD, targeting both glandular and extraglandular symptoms. Predicated on these data, a Phase Ib/IIa randomized controlled trial to treat SjD with tofacitinib was initiated.

Key messages (total 3-5 sentences)

What is already known on this topic?

- Upregulation of interferons (IFNs) has been reported in patients with SjD; however, a systematic investigation of their role at a cellular and tissue level in humans is lacking.
- What this study adds?

- Our findings conclusively show that the IFN-JAK-STAT pathway is activated in the
 salivary glands and PBMCs in patients with SjD
 - Specific cells in the MSGs (infiltrating lymphocytes, epithelial, antigen presenting cells, and endothelial cells) and in PBMCs (monocytes, NK cells, and dendritic cells) drive this IFN signature.
 - We pinpoint cells responsive to JAK inhibition and illustrate in patient tissues that JAK inhibitors may be beneficial in SjD by uncoupling the pathogenic cytokine milieu and resultant epithelial tissue damage and dysfunction central to SjD.

How this study might affect research, practice, or policy?

- SjD lacks an approved, efficacious and targeted therapy. Several large clinical trials have been unsuccessful due in part to a lack of biologically relevant endpoints or predictive biomarkers. We establish a multimodal testing platform using human tissues from SjD patients to identify actionable targets and to directly test treatment effects. Our data suggest that blocking the IFN-JAK-STAT pathway by using JAKi is a rational therapy for SjD. Moreover, these data can also serve as biological endpoints for clinical trials [NCT04496960].
- **Keywords** (< 5): Sjögren's Disease, Interferon, Janus kinases, STAT, Tofacitinib

Introduction

Despite being the second most common systemic autoimmune rheumatic disease, Sjögren's Disease (SjD) lacks a precise etiology or an approved and efficacious therapy that meaningfully manages symptoms or alters disease progression. Concerted efforts have been expended toward identifying the pathogenic mechanisms of SjD; these efforts have led to the development and testing of many medications to treat SjD. However, few agents met their primary endpoints until very recently, and only limited biological data accompany these studies. One of the reasons for these limitations could be the heterogeneous clinical presentation of patients with SjD. Chronic inflammatory lymphocytic infiltration of the exocrine glands leading to dysfunction and ultimate destruction of the tissue is characteristic of SjD. Most SjD patients

patients with SjD. Chronic inflammatory lymphocytic infiltration of the exocrine glands leading to dysfunction and ultimate destruction of the tissue is characteristic of SjD. Most SjD patients present with symptoms involving the salivary and lacrimal glands. Other tissues that can be affected include: the skin; the respiratory tract nervous system, kidneys, and the vagina, along with systemic symptoms including fatigue, widespread musculoskeletal pain, and polyarthritis.^{3 4}

Many of the inflammatory cytokines implicated in SjD pathogenesis, in particular Type-I and Type-II interferons (IFNs), interleukins (IL)-6, IL-7, IL-12, and IL-21, signal through the Janus Kinases (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway.⁵ However, a comprehensive understanding of IFN signaling and the involvement of the JAK-STAT pathway in SjD tissues is lacking. Clarification of cell types driving disease pathogenesis in the peripheral blood and in the salivary glands will facilitate the development of targeted therapies for SjD.

In this study, we aimed to characterize JAK-STAT pathway utilization in SjD-affected tissues and establish a human-tissue-based experimental rationale for examining the efficacy of JAK inhibitors (JAKi) in SjD participants. We used an 'omics' platform to identify high-potential

tractable pathways in the affected tissue compartments in SjD. We first performed 'bulk' RNA sequencing (RNAseq) on minor salivary glands (MSGs) from patients with SjD and demonstrated activation of the JAK-STAT pathway. These findings were corroborated using immunofluorescent staining (IF) of salivary glands, and flow cytometry analysis of the salivary glands and peripheral blood mononuclear cells (PBMCs) from patients with SjD. Using single cell RNAseq (scRNAseq), we were able to identify cells in the glands and peripheral blood that upregulate IFNs through the JAK-STAT pathway in MSGs and then confirmed these findings using flow cytometry and *ex vivo* culture assays. Finally, we used patients' tissues and primary cell models to show that JAKi can correct this altered pathway activation without cytotoxicity as a high-potential targeted therapy for SjD.

Materials and Methods

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

Subjects and ethical approval

Study subjects provided informed consent prior to the initiation of any study procedure, and they were evaluated and classified comprehensively according to 2016 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria. 6 Comparator group included subjects who did not meet 2016 ACR-EULAR criteria (non-SiD) or healthy volunteers (HV).⁷ All subjects were screened for evidence of systemic autoimmunity and received comprehensive oral/sialometric, rheumatological, and ophthalmological investigations. Clinical investigations were conducted in accordance with the Declaration of Helsinki principles. All studies using human samples were approved by the NIH IRB (15-D-0051, NCT00001390; 11-D-0172, NCT02327884, or 94-D-0018, NCT00001196; PI-Warner).

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

Patient and Public Involvement Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research. Human Salivary Gland RNA Sequencing Bulk RNA sequencing was performed as previously described.⁸ RNAseq data that passed quality control was deposited in dbGaP: phs001842.v1.p1. Single Cell RNA Sequencing of the MSGs and PBMCs MSG biopsies and PBMCs were processed for scRNAseq as previously described (supplemental table 1). 9 10 scRNAseq data sets were analyzed in Python using Scanpy. Immunofluorescence microscopy and analysis on MSGs Detection of JAK1 and JAK3 in MSG. FFPE MSG sections were processed following standard procedures. Sections were blocked, incubated in antibodies, and mounted (supplemental table 2). Immunofluorescence in primary cell culture assays. Primary salivary gland epithelial cells (pSGECs) were plated on chamber slides and stimulated as indicated, then stained with antibodies (supplemental table 2). Images were acquired on Nikon A1 HD (Nikon) confocal microscope and processed with CellProfiler in ImageJ (Broad Institute).¹¹ Flow cytometry Freshly biopsied MSGs were dissociated as described above. Multicolor flow cytometry was used to quantify the phosphorylation status of pSTATs in gated cell subset populations (supplemental table 2 and supplemental method 1, 2). Assessment of serum proteome

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

Proteomic profiles were measured in serum (50µL) using the SOMAscan Assay V1.3 (SomaLogic, Inc.) at the Trans-NIH Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health as previously reported.¹² RNA isolation and RT-qPCR Standard Taqman assays (supplemental table 3) were performed to measure relative gene expression. Statistical Analysis for Difference in Immune Cell Populations/Cytokines Statistical methods were employed using GraphPad Prism (GraphPad), MATLAB, or -R as described, and the type and nature of the data were considered when assessing differences in mean values and variances across biological and experimental replicates. A p-value of <0.05 was considered statistically significant. **Results** Genes in the JAK-STAT and Type-I IFN pathways are upregulated in MSGs from patients with SiDTo understand the transcriptome wide impacts of SjD on the MSGs, we first performed 'bulk' RNAseq on SjD and HV MSGs (figure 1A). Unsupervised clustering generally segregated SiD from HV MSGs based on differentially expressed genes (DEGs) (**figure 1B, C**). MSGs from SjD subjects were transcriptionally more active. Immune pathway genes, including ISGs (e.g., IFI44L, IFI44, MX1, CXCL13), were upregulated in SjD whereas canonical salivary genes were downregulated (**figure 1B, C**). Pathway enrichment analysis identified the JAK-STAT Pathway as one of the top significantly and differentially utilized pathway in SiD (figure 1D). Gene enrichment analysis showed consistent and direct regulation of the JAK-STAT pathway signaling

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

through IL7/IL15/IL21 via JAK3 (supplemental figure 1B). We examined the mRNA expression of JAK genes and found that JAKI had the highest expression in all MSGs whether they were from SjD or HV. However, when comparing MSGs from SjD to those from HV, JAK2 and JAK3, but not JAK1 or TYK2, expression was differentially increased (supplemental figure 1C). Although the bulk RNAseq was unable to reliably detect Type-I IFN transcripts, these data demonstrated increased *IFNG* (supplemental figure 1D). Thus, we employed surrogate readouts of Type-I and Type-II IFN gene expression using validated composite Type-I (21-gene)¹³ and Type-II (8-gene)¹⁵⁻¹⁷ IFN scores to demark patients with enhanced JAK-STAT pathway signaling. Calculated Type-I and Type-II IFN scores¹⁸ revealed 2-fold and 2.5-fold mean increases, respectively, in SjD patients' MSGs compared to HV glands (p=0.0033 and p=0.0009, respectively; **figure 1E, G**). Of the 24 SjD subjects, 17 (71%) had elevated Type-I or Type-II ISG scores; 7 exhibited elevations in both Type-I and Type-II IFN ISGs; while 5 each exhibited elevated Type-I or Type-II ISGs. Seven did not show significant elevation of either and were enriched for anti-SSA antibody negative subjects (5/7) (figure 1E, G). Type-I and Type-II ISG scores exhibited modest, positive, statistically significant correlation, but not all the variance was explained. Increased lymphocytic infiltration, quantified as a focus score (FS), is an independent predictor of deterioration of exocrine gland function. ¹⁹ SjD is related to both loss of epithelial cells and greater inflammation in the glands. The Type-I and Type-II IFN scores from our bulk RNAseq positively correlated with FS in the glands; however, Type-II IFN exhibited a stronger correlation than Type-I IFN ($R^2 = 0.24$, p = 0.0031 and $R^2 = 0.65$, p < 0.0001, respectively; **figure 1F, H**). Our data suggests that Type-II IFN signature serves as a surrogate for IFNy produced by T cells in the glands; while Type-I IFN signaling is appreciably more disease-specific and integrates the

contributions of the epithelial cells, dendritic cells, and monocytes in the MSG. Moreover, it is well-documented that there is positive crosstalk between Type-I IFNs (α and β) and Type-II IFN (γ) receptor signaling. In our cohort most patients exhibited elevated Type-I signaling. Thus, we focused on Type-I signaling in subsequent experiments, acknowledging that signaling *in vivo/in situ* is far more complex.

These findings confirm that SjD pathogenesis involves IFN-JAK-STAT pathway. However, "bulk" RNAseq does not precisely and robustly predict the compositional cell types or infer the cell states changes contributing to these phenomena in SjD-affected MSG.

Expression of JAK1 and JAK3 in the salivary glands is cell type-specific

To pinpoint the cell types and expression levels of JAK1 and JAK3 in the MSG, we used IF, whole slide imaging and analysis, and tSNE visualization (**figure 2A**). These results revealed the expected cellular proportion changes in the MSGs. Keratin-18 expression was restricted to epithelial structures (+6%, p<0.001; **figure 2B**, **C** and **supplemental figure 2A-C**). Per-cell JAK1 expression was mildly elevated in immune cells in SjD, while per-cell JAK3 expression showed both SjD-specific increased per-cell expression in epithelial cells and infiltrating immune cells in SjD (+35%, p<0.0001 and +15%, p<0.0001, respectively; **figure 2C**). It is generally assumed that high IFN signaling is driven by infiltration of immune cells; however, the IF and RNAseq results independently confirm that signaling is directed in part by the involved epithelium.

Increased phosphorylated STAT proteins in SjD MSGs confirm activation of JAK-STAT pathway

To directly confirm the activation status of the JAK-STAT pathway in MSGs, we measured the frequency of pSTAT proteins by flow cytometry in freshly biopsied and dissociated MSGs (**figure 2A**). In general, flow cytometry exhibited cellular proportion changes consistent with the IF results in the glands (**figure 2D**). The frequency of pSTAT1, pSTAT3(Ser727) and pSTAT6 proteins were higher at baseline in SjD epithelial cells compared to non-SjD (2.0-fold, p=0.017; 2.9-fold, p=0.028; and 6.9-fold, p=0.1080, respectively; **figure 2E**), directly supporting elevated activation of the JAK-STAT pathway in SjD epithelial cells. Moreover, the frequency of pSTAT proteins on immune cells showed a similar pattern in SjD-affected MSGs (1.4-fold, p=0.3749; 2.6-fold, p=0.068; and 1.2-fold, p=0.3499, respectively; **figure 2E**), with appreciably less significant differences.

High IFN signature and activated JAK-STAT pathway in SjD MSGs is due to salivary gland epithelial and infiltrating immune cells

Our results implicate coordinated interactions between the epithelium and the immune infiltrate (i.e., autoimmune epithelitis).³ To better understand the transcriptional impact of SjD on each cell type, we then analyzed single cell transcriptomes from MSGs from SjD and non-SjD subjects. Leiden clustering of scRNAseq data identified 11 clusters of cells representing the general cell types in the MSGs (**figure 3A** and **supplemental figure 3A**, **C**). Expectedly, compared to non-SjD MSGs—and consistent with both the IF and flow cytometry results—the proportion of seromucous acinar cells was reduced and immune cell infiltration was increased in SjD (**figure 3B**). Examining the top ten DEGs in each of the cell types demonstrated that SjD cells were dominated by ISGs (**figure 3C**). A Type-I IFN score was calculated for all cells in SjD and non-SjD and was increased in all cells in SjD patients' glands (**figure 3D**). Moreover, seromucous

acinar cells showed increased expression of multiple *JAK* genes, while ductal cells had increased expression of *JAK3* and *TYK2* (**figure 3E** and **supplemental figure 3C, D**). These results independently confirm our bulk and proteomics data and suggest that disease-specific utilization of this pathway in unique cell types.

Sera from SjD have increased IFN Signature

As a prototypic systemic autoimmune disease, additional non-exocrine organs are also commonly affected in SjD. To estimate proteomic changes in the circulation, Somalogic aptamer-based 1.3K target proteomics was performed. Most proteins were significantly upregulated in sera from SjD patients compared to controls (**figure 4B**). Consistent with MSGs data, inflammation and IFN regulated proteins were upregulated in sera. A validated 4-protein IFN score demonstrated a significant increase of IFN-stimulated proteins in SjD patients' sera compared to both non-SjD and HV sera (p<0.0001; **figure 4C**). These data indicate that IFN signatures in the glands are recapitulated in the blood and suggest similar pathogenic mechanisms affecting both tissue compartments.²

scRNA of PBMCs identify cells with activated JAK-STAT pathway

To better understand the transcriptional impact of SjD on each cell type in the peripheral blood, single-cell transcriptomes from PBMCs from SjD and non-SjD subjects were analyzed. scRNAseq identified 10 unique general types by Leiden clustering (**figure 4D** and **supplemental figure 4A**, **B**). DEG analysis showed upregulation of many ISGs (e.g., *IFI44L*, *IFIT3*, *ISG15*, *MX1*, and *IFI6*) in SjD PBMCs (**supplemental figure 4C**). Functional annotation analysis revealed that upregulated genes were mostly associated with immune and inflammatory responses, especially

'innate immunity against virus' and 'Type-I IFN responses' (figure 4E). Type-I IFN scores were projected on to each cell and were higher in SjD PBMCs compared to controls (figure 4F). Monocytes had the highest expression of ISGs in SjD, followed by dendritic cells, and then NK cells (figure 4F).

Increased phosphorylated STAT proteins in SjD PBMCs confirmed activation of JAK-STAT pathway in blood

To directly estimate the activation of the JAK-STAT pathway in the blood, the frequencies of pSTAT proteins were measured by flow cytometry of PBMCs from patients with SjD and HVs. The frequencies of basal pSTAT proteins, pSTAT1, pSTAT3(Ser727) and pSTAT6, were higher in SjD patients compared to HVs (2.0-fold, p=0.007, 2.3-fold, p=0.046, and 1.3-fold, p=0.044, respectively; **figure 5** and **supplemental figure 5**). Of note, pSTAT3(Ser727), but not pSTAT3(Tyr705) was significantly upregulated in SjD patients. In aggregate, these findings indicate that enhanced Type-I IFN response in PBMCs could be involved in both the systemic aspect of SjD and local inflammation after infiltration into the MSGs. Our results suggest that we could employ this tissue as a surrogate model for assessing if identified drugs are biologically effective for SjD or stratify patients amenable to pathway targeting, *a priori*.

Tofacitinib inhibits Type-I IFN response in PBMCs

Based on our transcriptomic and proteomic data, SjD pathogenesis may be selectively dependent on JAK3 and JAK1 in both immune and epithelial compartments. Thus, we tested the effectiveness of the JAK3/JAK1 semi-selective inhibitor, tofacitinib, in *ex vivo/in vitro* assays (**figure 6A**). Treatment with 5 μM tofacitinib blocked STATs phosphorylation status induced by

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

IFNβ stimulation in PBMCs in all cell subsets without inducing cytotoxicity (figure 6B and supplemental figure 6A, D). scRNAseq showed that 5 μM tofacitinib downregulated 109 DEG, nearly all of which were ISGs, and no genes were upregulated. To facitinib suppressed the IFNβinduced IFN signature to baseline levels (**figure 6C, D** and **supplemental figure 6B**). Cell clusters with sufficient number of representation of samples and cells in each treatment group cluster were analyzed for top DEG by pseudobulk analysis. T cells and monocytes exhibited greater numbers of downregulated ISGs in the context of tofacitinib inhibition. ISGs were among the top DEG in all subsets after IFNB stimulation and tofacitinib normalized this response; cell type-specific effects were less dominant (figure 6E). A similar direction of effect was shown in PBMCs treated with 5μM tofacitinib without IFNβ stimulation, though there was appreciable inter-individual variability in responsiveness to tofacitinib (supplemental figure 6C). These data provide clear and direct evidence, using affected human tissues from SjD patients, that in vitro tofacitinib can abrogate basally activated JAK-STAT signaling and suggest that responsiveness to JAK inhibition is somewhat SjD-selective. These results raised the question as to whether a similar correction could be achieved in glandular epithelial cells.

Tofacitinib, a JAK inhibitor, reduces Type-I IFN response in primary salivary gland epithelial cells

To model the glandular epithelial response to Type-I IFN and blockade by tofacitinib, we used primary salivary gland epithelial cells derived and cultured from SjD and HV. Tofacitinib at 5µM concentration did not induce apoptosis or necrosis in pSGEC (**supplemental figure 7A, B**). Tofacitinib mitigated IFN β -induced pSTAT1 proteins in both the nucleus and cytosol in pSGECs as assessed by IF (0.78-fold, p<0.0001; 0.84-fold, p<0.0001, respectively; **figure 7B**), and dose-

dependently decreased IFN β -induced ISGs mRNA expression (*CXCL10*: 0.002-fold, p=0.023; *ISG15*: 0.03-fold, p=0.003; *MX1*: 0.01-fold, p=0.009; **figure 7C** and **supplemental figure 7C**). Of note, SjD-derived pSGECs exhibited an enhanced response to IFN β stimulation (e.g., *CXCL10*: 33.6-fold, p=0.032; **figure 7C**). pSGECs treated with tofacitinib without IFN β stimulation showed a trend towards decreased expression of ISGs, though this was not statistically significant (**supplemental figure 7D**). These results suggest that i) responsiveness to JAK inhibition is activation-dependent and SjD-selective, and ii) while activation is not retained in pSGECs in vitro, pSGECs do retain SjD-specific enhanced responsiveness to IFN stimulation²⁰ supporting the robustness of this model system.

Discussion:

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

Current strategies for managing SiD are ineffective in limiting disease progression or preventing the long-term decline in quality of life. Recent successes of early stage randomized controlled trials in SjD (BAFF-R, TACI, CD40, CD40L²¹) offer renewed optimism to patients and providers. Given the multiple intersecting pathogenic pathways driving varied clinical presentations in SiD, and a paucity of successful trials, there is continued need for biologically relevant, effective, and targeted therapeutics. Rational repurposing of approved drugs offers an exciting path to accelerate the approval of safe and effective medications for patients with SiD. To this end, we established a multimodal testing platform using human tissues from SjD patients to identify actionable targets and to directly test biological effects. Specifically, we hone-in on Type-I IFN signaling through the JAK-STAT pathway. The activation of the IFN pathway in SjD patients' peripheral blood has been reported²², but the specific cell types driving this upregulation in blood or in the glands remain poorly detailed. Using transcriptomic and functional approaches on peripheral blood and MSG tissue from SjD patients, our data revealed enhanced IFN signaling via JAK-STAT in both compartments, emphasizing the therapeutic potential of this pathway. We identified cell subsets driving this activated state: monocytes, NK cells and DCs in PBMCs and infiltrating immune cells and salivary gland epithelial cells in MSGs. Our data confirm SjD-specific upregulation of ISGs and JAK-STAT pathway in salivary glands and blood, aligning with previous reports.²³ These cytokines, via Janus Kinases, initiate and enhance inflammation in SjD salivary glands.^{2 24-28} Similar to a previous report, the elevated IFN signatures in MSG correlated with clinical variables including

focus score and enrichment in autoantibody-positive subjects.²⁹

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

To understand the upstream effects in SjD-affected MSG, we measured JAK genes and protein expression in the glands at single cell resolution. Among the JAK genes expressed in the MSGs, JAK1 was most abundant and ubiquitously expressed in both SiD and non-SiD. However, JAK3 mRNA and protein expression was only elevated in SiD. Using IF on MSGs, JAK1 protein localized to immune and epithelial cells with a very slight increased expression (~6%) in SjD immune cells likely due to increased expression in APCs as found in scRNAseq. Confirming our bulk and scRNAseq data, IF showed that JAK3 protein was increased in i) the ductal and acinar epithelium in SjD involved by focal lymphocytic inflammation, and ii) in inflammatory cells within inflammatory foci. A previous report showed JAK1 staining in ductal cells, and to a lesser extent in acinar cells, in HV and SjD patients.³⁰ We extend the understanding of JAK-STAT signaling in the gland by showing the novel finding of disease-specific dependence of JAK3 signaling in the ductal epithelium. These data provide guidance for rational drug selection (i.e., a JAK3/JAK1 targeting drug such as tofacitinib) whereby the epithelium and disease-specific immune infiltrates show evidence of dependence on JAK-STAT signaling through JAK3/JAK1 in SjD. Deciphering the JAK-STAT pathway involvement in SjD is an exciting area of investigation. We and others have demonstrated significantly increased *IL21* and IL-21-inducible genes: JAK3 and STAT1 in SjD via RNAseq of MSGs.31 pSTAT1 in SjD MSG biopsies has been associated with IFN-α, IFN-γ, and IL-6 stimulation. 32 33 Very recently, pSTAT1 was shown to confer histopathological value in MSGs with or without lymphocytic foci³⁴; however, these findings are based on weak intensity immunohistochemical staining of pSTAT1 without rigorous quantification. We now directly confirmed that pSTAT1 and pSTAT3(Ser727) are elevated in the epithelial and immune cells in the MSGs by phospho-flow cytometry from SjD subjects. It has

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

been reported that STAT protein expression is increased in immune cells of MSG.³² ³³ ³⁵ Furthermore, our transcriptomic (bulk and sc) results show that STATs gene expressions are upregulated in SjD, and our proteomic data establishes that the levels of pSTATs are higher in SjD MSG than controls. These data further confirm that activated JAK-STAT signaling is a potentially targetable pathogenetic factor for SjD.

Our data supports that activation of IFN pathway in SjD is a systemic phenomenon and not constrained to the salivary glands.³⁶ Enhanced IFN response in PBMCs could be involved in both the systemic features of SiD and local inflammation after infiltration into MSGs. T cells could proliferate locally in the salivary glands, but much of their infiltration is from migration from the circulation.³⁶ In PBMCs from SjD subjects, pSTAT1 frequency was significantly higher compared to controls and was more of a general phenomenon across multiple cell subsets. On the other hand, pSTAT3(Ser727), but not -(Tyr705), were more frequently phosphorylated in SjD T cells, NK cells, and monocytes (supplemental figure 5). pSTAT3(Ser727) has been suggested to contribute to oxidative phosphorylation in the mitochondria with an effect that is independent of STAT3(Tyr705) phosphorylation.³⁷ Davies et al.³⁸ showed increased responses from B cells in peripheral blood from patients with SjD to TLR-7 and -9 agonism were dependent upon phosphorylation of STAT3 at the Ser727 site. It has been reported that Tyr705 phosphorylation is essential for STAT dimerization, nuclear translocation and DNA binding, whereas C-terminal Ser727 phosphorylation is required for maximal transcriptional activity.³⁹ The increased response was found to be correlated with Type-I IFN signature suggesting that pSTAT3(Ser727) plays a key role in IFN signaling in SjD patients and could be a potential molecule for targeted therapy or to monitor therapeutic effects of targeted therapies. These results support i) the independence of Ser727 from Tyr705 on pSTAT3, and *ii*) possibly highlight patients with maximal pathway activation who may benefit from JAKi.

JAKi have emerged as an important new class of oral therapy for several autoimmune diseases. 40 41 Tofacitinib was the first oral JAK inhibitor approved for rheumatoid arthritis. It blocks JAK3 and JAK1 but also has a role in JAK2 and TYK2 inhibition. 42-46 Our *ex vivo* experiments using pSGECs and PBMCs consistently demonstrated that tofacitinib treatment suppressed JAK-STAT pathway activation in a dose-dependent manner, as shown by downregulated pSTAT levels, decreased IFN signature and ISG expression. Of note, basal elevations in pSTAT levels were selectively controlled by tofacitinib in SjD patients' PBMCs, but not controls. Similar to our results, recently baricitinib, a semi-selective inhibitor of JAK1 and JAK2, mitigated IFN-γ-induced CXCL10 production in salivary gland ductal cell line. 30

Cell type differences in responsiveness have been reported with regards to the potency of JAKi to inhibit cytokine signaling. A 3-fold difference was observed in the JAK1/TYK2-dependent IFN-stimulated pSTAT1 between CD4+ T cells and monocytes, whereas the potencies were comparable for B and NK cells.⁴⁷ For the reactivity of each pSTAT, JAK inhibition of JAK1/TYK2-mediated IFNα-driven pSTAT5 and pSTAT3 was more potent than pSTAT1, potentially demonstrating the reliance on TYK2 for regulating STAT1 phosphorylation.⁴⁸ In our study, pSTATs (e.g., pSTAT1, pSTAT3(Ser727), pSTAT6) in T cells showed consistent sensitivity to JAKi treatment. Other cell subsets also demonstrated pSTAT specific sensitivity (B cells – pSTAT1; NK cells–pSTAT1/6). Our findings suggest that pathogenic inflammatory signaling through specific JAKs may identify selective therapeutic drug choice.

Limitations of this study include relatively modest sample sizes used for fresh tissue analyses. The prospective use of fresh tissues poses logistical challenges including recruitment and

adequate tissue recovery for both clinical and research purposes. Despite these limitations, we demonstrate biologically meaningful changes in JAK-STAT pathway in glandular and peripheral blood samples and direct responsiveness to JAKi. These limitations are addressed by using multiple different experimental approaches to systematically and comprehensively evaluate the IFN-JAK-STAT pathway in SjD.

In conclusion, SjD patients have increased IFN signature with activated JAK-STAT pathway which plays a key role in both the glandular and extraglandular pathogenesis of SjD. This activation is cell specific, with salivary epithelial cells and infiltrating immune cells driving the bulk of this signature in MSGs. The activated IFN-JAK-STAT signature is also seen in peripheral blood, highlighting the dysregulated systemic immune system in SjD. Modulation of the JAK-STAT pathway, through JAKi was non-cytotoxic and effective *ex vivo* using human tissues. These results suggest tofacitinib as a potential therapeutic strategy for SjD patients and serve as the basis of an open and enrolling Phase Ib/IIa randomized controlled trial to treat SjD with tofacitinib (NCT04496960).

425

426

427

428

429

430

431

432

433

434

435

436

437

438

Potential Conflicts of Interest: BMW has Cooperative Research Award and Development Agreements [CRADA] from Pfizer, Inc., and Mitobridge, Inc. (A subsidiary of Astellas Pharma, Inc.). NIAMS has CRADAs with Astra Zeneca and Bristol Myers Squibb. These CRADA did not financially support the experimental results presented herein. Funding/Support: This research was principally supported through research awards to BMW from the Division of Intramural Research (DIR) Program of the National Institute of Dental and Craniofacial Research of the National Institutes of Health (NIH/NIDCR ZIA: DE000704). Additional funding and support from the DIR Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH (NIH/NIAMS ZIA: AR041199). **Acknowledgements:** The authors provide their emphatic appreciation to the subjects for their unwavering support of our clinical studies through their volunteerism. We also thank the support and staff of the NIDCR Office of the Clinical Director, NIDCR Dental Clinic, the National Eye Institute Ophthalmology Clinic, and the NCI Center for Cancer Research Anatomic Pathology.

References

439

457

458

459

460

461

462

463

464

465

466

467

468

- Mavragani CP, Moutsopoulos HM. Sjögren's syndrome: Old and new therapeutic targets. *J Autoimmun* 2020;110:102364. doi: 10.1016/j.jaut.2019.102364 [published Online First: 20191209]
- 2. Hall JC, Baer AN, Shah AA, et al. Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome. *Arthritis Rheumatol* 2015;67(9):2437-46. doi: 10.1002/art.39204
- 3. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. *Clin Immunol Immunopathol* 1994;72(2):162-5. doi: 10.1006/clin.1994.1123
- 4. Mariette X, Criswell LA. Primary Sjögren's Syndrome. *N Engl J Med* 2018;378(10):931-39.
 doi: 10.1056/NEJMcp1702514
- 5. Gandolfo S, Ciccia F. JAK/STAT Pathway Targeting in Primary Sjögren Syndrome.
 Rheumatol Immunol Res 2022;3(3):95-102. doi: 10.2478/rir-2022-0017 [published
 Online First: 20221020]
- 6. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European
 League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A
 Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.
 Arthritis Rheumatol 2017;69(1):35-45. doi: 10.1002/art.39859 [published Online First:
 20161026]
 - 7. Warner BM, Baer AN, Lipson EJ, et al. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. *Oncologist* 2019;24(9):1259-69. doi: 10.1634/theoncologist.2018-0823 [published Online First: 20190417]
 - 8. Jang S-I, Tandon M, Teos L, et al. Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome. *eBioMedicine* 2019;48:526-38. doi: 10.1016/j.ebiom.2019.09.010
 - 9. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med* 2021;27(5):892-903. doi: 10.1038/s41591-021-01296-8 [published Online First: 20210325]
 - 10. Yin H, Pranzatelli TJF, French BN, et al. Sclerosing Sialadenitis Is Associated With Salivary Gland Hypofunction and a Unique Gene Expression Profile in Sjögren's Syndrome. *Front Immunol* 2021;12:699722. doi: 10.3389/fimmu.2021.699722 [published Online First: 20210730]
- 470 11. Stirling DR, Swain-Bowden MJ, Lucas AM, et al. CellProfiler 4: improvements in speed,
 471 utility and usability. *BMC Bioinformatics* 2021;22(1):433. doi: 10.1186/s12859-021472 04344-9 [published Online First: 20210910]
- 12. Candia J, Cheung F, Kotliarov Y, et al. Assessment of Variability in the SOMAscan Assay.
 Sci Rep 2017;7(1):14248. doi: 10.1038/s41598-017-14755-5 [published Online First: 20171027]
- 13. Yao Y, Higgs BW, Morehouse C, et al. Development of Potential Pharmacodynamic and
 Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus
 Erythematosus. *Hum Genomics Proteomics* 2009;2009 doi: 10.4061/2009/374312
 [published Online First: 20091117]
- 14. Gupta S, Tatouli IP, Rosen LB, et al. Distinct Functions of Autoantibodies Against Interferon
 in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine
 Autoantibodies in Common Rheumatic Diseases. *Arthritis Rheumatol* 2016;68(7):1677 87. doi: 10.1002/art.39607

- 484 15. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. *Arthritis Res* 485 *Ther* 2003;5(6):279-87. doi: 10.1186/ar1015 [published Online First: 20031013]
- 486 16. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. *Arthritis Rheum* 2005;52(5):1491-503. doi: 10.1002/art.21031

- 17. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. *Proc Natl Acad Sci U S A* 2003;100(5):2610-5. doi: 10.1073/pnas.0337679100 [published Online First: 20030225]
- 18. Smith MA, Chiang CC, Zerrouki K, et al. Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. *Sci Rep* 2020;10(1):4462. doi: 10.1038/s41598-020-60563-9 [published Online First: 20200310]
- 19. Haldorsen K, Moen K, Jacobsen H, et al. Exocrine function in primary Sjögren syndrome: natural course and prognostic factors. *Ann Rheum Dis* 2008;67(7):949-54. doi: 10.1136/ard.2007.074203 [published Online First: 20071025]
- 498 20. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role
 499 in health and disease. *Nat Rev Immunol* 2020;20(6):375-88. doi: 10.1038/s41577-020 500 0285-6 [published Online First: 20200304]
- Seror R, Nocturne G, Mariette X. Current and future therapies for primary Sjögren
 syndrome. *Nature Reviews Rheumatology* 2021;17(8):475-86. doi: 10.1038/s41584-021-00634-x
 - 22. Marketos N, Cinoku I, Rapti A, et al. Type I interferon signature in Sjögren's syndrome: pathophysiological and clinical implications. *Clin Exp Rheumatol* 2019;37 Suppl 118(3):185-91. [published Online First: 2019/08/04]
 - 23. Nordmark G, Alm GV, Rönnblom L. Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system. *Nat Clin Pract Rheumatol* 2006;2(5):262-9. doi: 10.1038/ncprheum0173
 - 24. Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. *J Autoimmun* 2015;63:47-58. doi: 10.1016/j.jaut.2015.07.002 [published Online First: 20150714]
 - 25. Soret P, Le Dantec C, Desvaux E, et al. A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. *Nat Commun* 2021;12(1):3523. doi: 10.1038/s41467-021-23472-7 [published Online First: 20210610]
 - 26. Ha YJ, Choi YS, Kang EH, et al. Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren's syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. *Clin Exp Rheumatol* 2018;36 Suppl 112(3):31-40. [published Online First: 2017/04/20]
- 521 27. Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary
 522 Sjögren's syndrome: a possible etiopathogenic mechanism. *Arthritis Rheum* 523 2005;52(4):1185-95. doi: 10.1002/art.20998 [published Online First: 2005/04/09]
- 28. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. *Proc Natl Acad Sci U S A* 2006;103(8):2770-5. doi: 10.1073/pnas.0510837103 [published Online First: 20060213]
- 29. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity
 define the origin of interferon signatures in target tissues in rheumatic diseases. *Proc Natl*

- 530 *Acad Sci U S A* 2012;109(43):17609-14. doi: 10.1073/pnas.1209724109 [published 531 Online First: 20121008]
- 30. Aota K, Yamanoi T, Kani K, et al. Inhibition of JAK-STAT Signaling by Baricitinib Reduces
 Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
 Inflammation 2021;44(1):206-16. doi: 10.1007/s10753-020-01322-w
- 31. Chen X, Jiang S, Zhou Z, et al. Increased expression of interleukin-21-inducible genes in minor salivary glands are associated with primary Sjögren's syndrome disease characteristics. *Rheumatology (Oxford)* 2021;60(6):2979-89. doi: 10.1093/rheumatology/keaa695
- 32. Wakamatsu E, Matsumoto I, Yasukochi T, et al. Overexpression of phosphorylated STAT 1alpha in the labial salivary glands of patients with Sjögren's syndrome. *Arthritis Rheum* 2006;54(11):3476-84. doi: 10.1002/art.22176
- 33. Pertovaara M, Silvennoinen O, Isomäki P. Cytokine-induced STAT1 activation is increased
 in patients with primary Sjögren's syndrome. *Clin Immunol* 2016;165:60-7. doi:
 10.1016/j.clim.2016.03.010 [published Online First: 20160317]
 - 34. Zheng Q, Liu L, Wang B, et al. Phosphorylated signal transducer and activator of transcription proteins 1 in salivary glandular tissue: an important histological marker for diagnosis of primary Sjögren's syndrome. *RMD Open* 2023;9(1) doi: 10.1136/rmdopen-2022-002694
 - 35. Vartoukian SR, Tilakaratne WM, Seoudi N, et al. Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjögren's syndrome. *Clin Exp Immunol* 2014;177(3):618-29. doi: 10.1111/cei.12377
- 36. Singh N, Cohen PL. The T cell in Sjogren's syndrome: force majeure, not spectateur. *J* Autoimmun 2012;39(3):229-33. doi: 10.1016/j.jaut.2012.05.019 [published Online First: 20120617]
 - 37. Reich NC. STAT3 revs up the powerhouse. *Sci Signal* 2009;2(90):pe61. doi: 10.1126/scisignal.290pe61 [published Online First: 20090929]
 - 38. Davies R, Sarkar I, Hammenfors D, et al. Single Cell Based Phosphorylation Profiling Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary Sjögren's Syndrome. *Front Immunol* 2019;10:281. doi: 10.3389/fimmu.2019.00281 [published Online First: 20190221]
 - 39. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. *Drug Resist Updat* 2010;13(3):67-78. doi: 10.1016/j.drup.2010.04.001 [published Online First: 20100514]
- 40. Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to
 clinical practice. *Rheumatology (Oxford)* 2019;58(Suppl 1):i4-i16. doi:
 10.1093/rheumatology/key432
- 41. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases.
 Ann Rheum Dis 2013;72 Suppl 2(0 2):ii111-5. doi: 10.1136/annrheumdis-2012-202576
- 570 42. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. 2017
- 571 43. Xeljanz (tofacitinib) prescribing information. 2022
- 572 44. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med* 2012;367(6):508-19. doi:
- 574 10.1056/NEJMoa1112072

546

547

548

549

550

551

552

556

557

558

559

560

561

562 563

45. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis.
 N Engl J Med 2014;370(25):2377-86. doi: 10.1056/NEJMoa1310476

- 46. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet* 2017;390(10093):457-68. doi: 10.1016/s0140-6736(17)31618-5 [published Online First: 20170616]
- 47. Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. *Ann Rheum Dis* 2021;80(7):865-75. doi: 10.1136/annrheumdis-2020-219012 [published Online First: 20210319]
- 48. Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. *Sci Transl Med* 2019;11(502) doi: 10.1126/scitranslmed.aaw1736

Figure Legends

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

Figure 1: Bulk sequencing of minor salivary gland and IFN signature

(A) Overview of MSG biopsy and whole transcriptomic analysis using RNAseq from 22 SjD and 11 HV. (B) Heatmap illustrating the top 250 DEGs in MSG between SjD and HV highlighting multiple ISGs, cytokines, and interleukins, in the DEG. Immune pathway genes, including ISGs (e.g., IFI44L, IFI44, MX1, CXCL13), were upregulated whereas canonical salivary genes (e.g., BPIFB2, PIP, ZG16B) were down regulated in SjD. (C) Similarly, a volcano plot showing the DEGs between SiD and HV, in which some representative genes were highlighted. MSGs from SjD subjects were transcriptionally more active with 2773 upregulated versus 468 downregulated genes. (D) Pathway enrichment analysis identified JAK-STAT Pathway as one of the top three differentially utilized pathway amongst the 25 significantly enriched pathways in SjD at a padj<0.01 (E, G) Calculated Type-I and Type-II IFN scores revealed 2 through 2.5-fold mean increases in SjD MSGs compared to HV. Differences in mean values were compared using the Mann-Whitney U-test at a p < 0.05 deemed significant. (F, H) The activated IFN signature noted in our bulk RNAseq positively correlated with FS in the glands. Spearman correlation analysis was used to assess the significance between correlated values at a p < 0.05. MSG, minor salivary gland; RNAseq, RNA sequencing; SjD, Sjogren's Disease; HV, healthy volunteer; DEGs, differentially expressed genes; ISG, interferon stimulated genes; FS, focus score.

Figure 2: Immunofluorescence microscopy

(A) Overview of MSG biopsy, image acquisition and flow cytometry. (B) MSG IF image showing upregulated expression of JAK1 and JAK3 in SjD epithelial and infiltrating immune cells. JAK3 was especially enrich in ductal cells. Cellular proportion changes in the SjD MSGs showed greater

numbers of immune cells, less numbers of epithelial cells. (C) Mean fluorescence of KRT18, JAK1 and JAK3 in SjD and non-SjD showing cellular proportion in the MSGs. Expression of JAK1 localized to immune cells (+6%; p<0.0001, Mann-Whitney Test) but JAK3 expression was seen in both epithelial and infiltrating immune cells (35% and 15%, respectively; p<0.0001, Mann-Whitney Test). (D) Cellular population change in 7 SjD and 6 non-SjD was characterized by flow cytometry showed reduced numbers of epithelial cells and increased numbers of infiltrating immune cells in SjD MSGs compared to controls. (E) Flow cytometry of MSG represented the frequency of pSTAT proteins: pSTAT1 (2.1-fold, p=0.017), pSTAT3(Ser727) (2.2-fold, p=0.031), and pSTAT6 (3.3-fold, p=0.112) were higher at baseline in SjD epithelial cells compared to non-SjD. Although not reaching the threshold of statistical significance, the frequency of pSTAT proteins (i.e., pSTAT3(Ser727) (p=0.056)) on CD45+ cells showed a similar frequency of pSTAT proteins in the SjD MSG. P value was calculated using Welch's test. MSG, minor salivary gland; IF, immune fluorescent; SjD, Sjogren's Disease; KRT18, Keratin-18.

Figure 3: Single cell RNAseq and pSTATs frequencies of MSG

(A) UMAP embedding of the entire dataset colored by generated clusters labelled by cell type annotation. From all profiled MSG samples from 7 SjD and 5 non-SjD, Leiden clustering identified 11 different cell clusters corresponding to mucous (*MUC5B*) and seromucous acinar cells (*MUC7*), ductal cells (*S100A2*), plasma cells (*IGHA*, *IGHG1*), fibroblasts (*COL1A2*), myoepithelial (*KRT14*), pericytes (*ACTA2*), B-cells (*CD79A*), antigen presenting cells (*HLA-DRA*, *CD68*), T-lymphocytes (*CD3D*), and erythrocytes (*HBB*) (n=51736 cells). (B) Differential of cell density showing increased immune cell infiltration in SjD. (C) The top ten DEG in each of the cell types were dominated by ISGs including increased expression *B2M*, *HLA-B*, *SAA1*, *IL32*, and *MGP*. (D)

Differential expression of IFN score in SjD and non-SjD, immune cells showed the biggest fold-changes in IFN score were in infiltrating immune cells (e.g., plasma cells: 700-fold, APCs: 400-fold; T cells: 300-fold; seromucous cells: 250-fold; ductal epithelial cells: 250-fold) exhibited higher IFN scores. (E) Fold change expression of JAK-STAT genes on all cell types. *JAK1* was the most ubiquitously expressed in MSGs and Seromucous acinar cells showed increased expression of all *JAKs*. UMAP, Uniform manifold approximation and projection; MSG, minor salivary gland; SjD, Sjogren's Disease; DEG, differentially expressed genes.

Figure 4: Single cell RNAseq and pSTATs frequencies of PBMC

(A) Overview of using patient's serum and PBMC for several assays. (B) Somalogic aptamer-based 1.3K target proteomics analysis revealed most of proteins were significantly upregulated in serum from SjD in volcano plot showing protein expression, in which some representative genes were highlighted. (C) IFN regulated proteins were found to be upregulated in SjD serum (*p*<0.0001). P value was calculated using Kruskal-Wallis test. (D) UMAP embedding of the entire dataset colored by generated clusters labelled by cell type annotation. Leiden clustering identified 10 different cell clusters from all profiled PBMC samples from 8 SjD and 6 non-SjD (n=206687 cells). (E) The upregulated genes were associated with immune and inflammatory responses revealed by functional annotation analysis from PBMC scRNAseq. (F) Differential expression of IFN score, monocytes had the highest expression of ISGs, followed by dendritic cells and then NK cells. SjD, Sjogren's Disease; UMAP, Uniform manifold approximation and projection; RNAseq, RNA sequencing; ISG, interferon stimulated genes.

Figure 5: Basal pSTATs frequencies in PBMCs

(A-D) Flow cytometry analysis revealed basal pSTATs levels in PBMCs were upregulated in 21 SjD compared to 10 HV. P value was calculated using Welch's test. SjD, Sjogren's Disease; HV, healthy volunteer.


Figure 6: Treatment effects of tofacitinib in PBMCs

(A) Overview of using PBMC treated by tofacitinib for scRNAseq and FACS. PBMCs were treated with or without 5mM tofacitinib for 1 hour prior to IFNβ treatment for 30 minutes or 6 hours, respectively. (B) Treatment with tofacitinib blocked STATs phosphorylation status induced by IFNβ stimulation in PBMCs from SjD. P value was calculated using Mann-Whitney test. (C) UMAP embedding of the entire dataset colored by generated clusters labelled by 4 general cell type annotations. (D) Differential utilization of IFN signature of each condition showed tofacitinib abolished the IFNβ-induced IFN score to baseline level. (E) Volcano plot showing DEGs by pseudobulk analysis across SjD and HV, in which some representative genes were highlighted. T cells (129 genes) and monocytes (61 genes) exhibited greater numbers of downregulated ISGs in the context of tofacitinib. ISGs (e.g., *IFIT1*, *IFIT3*) were among the top DEG in all subsets after IFNβ and tofacitinib normalizing this response. RNAseq, RNA sequencing; SjD, Sjogren's Disease; DEG, differentially expressed genes; HV, healthy volunteer; ISG, interferon stimulated genes.

Figure 7: Treatment effects of tofacitinib in pSGECs

(A) Overview of using pSGEC treated by tofacitinib for IF and RT-qPCR. pSGEC were derived from fresh MSG biopsies. (B, C) Differential expression of pSTAT1 in pSGECs. Tofacitinib treatment mitigated IFNβ-induced STAT1 phosphorylation in both the nucleus and cytosol. P

value was calculated using Kruskal-Wallis test. (D) Expression change of ISGs (*i.e.*, *CXCL10*, *ISG15*, *MX1*) on pSGECs showing dose-dependently decreased IFNβ-induced ISGs mRNA expression. 5 SjD and 5 HV (n=5 individuals' lines, respectively). 1 SjD and 1 HV samples were eliminated from MX1 result. P value was calculated using Mann-Whitney test and Kruskal-Wallis test. pSGEC, primary salivary gland epithelial cells; SjD, Sjogren's Disease; HV, healthy volunteer; ISG, interferon stimulated genes.






Figure 2




Figure 2








Figure 3












Figure 7




Figure 7